4 analysts have expressed different opinions on Autolus Therapeutics AUTL in the last quarter, offering a diverse set of views from bullish to bearish.
The table below summarizes their recent ratings, offering a look at the evolution of sentiments over the last 30 days and comparing them to previous months.
| Bullish | A little bullish | Indifferent | A little bearish | Bearish | |
|---|---|---|---|---|---|
| Total ratings | 4 | 0 | 0 | 0 | 0 |
| Last 30 days | 1 | 0 | 0 | 0 | 0 |
| 1 million ago | 1 | 0 | 0 | 0 | 0 |
| 2 million ago | 2 | 0 | 0 | 0 | 0 |
| 3 million ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets rated by analysts reveal further insights, with an average target of $9.0, a high estimate of $10.00 and a low estimate of $8.00. This current average is up 9.09% from the previous average price target of $8.25.
Decoding Analyst Ratings: A Detailed Look
Autolus Therapeutics’ position among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent ratings, and adjustments to ratings and price targets.
| Analyst | Analytics company | Action taken | Assessment | Current price target | Previous price target |
|---|---|---|---|---|---|
| Gil Blum | Fiduciary Securities | Raise | Acquire | $10.00 | $9.00 |
| Gil Blum | Needham | Maintains | Acquire | $9.00 | $9.00 |
| Gil Blum | Needham | Raise | Acquire | $9.00 | $8.00 |
| Gil Blum | Needham | Raise | Acquire | $8.00 | $7.00 |
Key Insights:
- Action taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they “maintain”, “raise” or “lower” their position, this indicates their reaction to recent developments related to Autolus Therapeutics. This view provides a snapshot of analysts’ perspectives on the current state of the company.
- Assessment: Gaining insights, analysts provide qualitative ratings, ranging from “Outperform” to “Underperform.” These ratings reflect expectations for Autolus Therapeutics’ relative performance compared to the broader market.
- Price targets: By gaining in-depth information, analysts provide estimates for the future value of Autolus Therapeutics stock. This comparison reveals the trend in analyst expectations over time.
Evaluating these analyst ratings along with crucial financial indicators can provide a comprehensive overview of Autolus Therapeutics’ market position. Stay informed and make informed decisions with the assistance of our scorecard.
Stay updated on the ratings of Autolus Therapeutics analysts.
If you’re interested in following the news and performance of small-cap stocks, you can start by tracking them here.
Get to know Autolus Therapeutics better
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The Company’s clinical-stage pipeline includes Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 and AUTO8.
Autolus Therapeutics: financial performance analyzed
Market capitalization analysis: With a high market capitalization, the company stands out from industry averages, demonstrating considerable scale and market recognition.
Negative revenue trend: Examining Autolus Therapeutics’ 3-month financials reveals some challenges. As of September 30, 2023, the company had a decline of approx -82.86% in revenue growth, reflecting a decline in top-line earnings. Compared to its peers, revenue growth lags that of industry peers. The company achieved a below-average growth rate among its healthcare peers.
Net margin: Autolus Therapeutics’ net margin falls below industry averages, indicating difficulty achieving strong profitability. With a clear margin of -11292.86%, the company may face obstacles in managing costs effectively.
Return on equity (ROE): Autolus Therapeutics’ ROE is lower than industry averages, indicating that it is difficult to use equity capital efficiently. With an ROE of -22.37%, the company may face obstacles in generating optimal returns for shareholders.
Return on Assets (ROA): Autolus Therapeutics’ ROA is lower than industry averages, suggesting that it is difficult to maximize returns from its assets. With an ROA of -10.7%, the company may encounter obstacles in achieving optimal financial performance.
Debt Management: The company maintains a balanced approach to debt, with a debt-to-equity ratio below industry norms 0.29.
How are analyst ratings determined?
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually over the next five years, and how risky or predictable the company’s revenue streams will be.
Analysts participate in conference calls and company meetings, research companies’ financial statements, and communicate with insiders to publish their stock ratings. Analysts typically rate each stock once a quarter or whenever the company has a major update.
In addition to their ratings, some analysts extend their insights by offering forecasts for key metrics such as earnings, revenue and growth estimates. This additional information provides further guidance for traders. It is critical to recognize that despite their specialization, analysts are human and can only provide predictions based on their beliefs.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.